| Christine Filippone, NP | |
|
1870 Dino Blvd, Toms River, NJ 08755-1343 | |
| (908) 783-5486 | |
| (732) 557-8956 |
| Full Name | Christine Filippone |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 46 Years |
| Location | 1870 Dino Blvd, Toms River, New Jersey |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114088606 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2200X | Nurse Practitioner - Adult Health | 66595 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ocean County Health Department | 9931108180 | 5 |
News Archive
An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del mutation in the CFTR gene, which is estimated to represent almost 90 percent of the cystic fibrosis population in the United States.
A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma.
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that it has completed its previously announced acquisition of the Interactive Voice and Web Response Services (IVRS/IWRS) business of Covance Inc. (NYSE: CVD). Phase Forward purchased the Covance business unit for $10 million in cash. As part of the transaction, Phase Forward and Covance have entered into a multi-year marketing agreement to provide Phase Forward's market-leading InForm™ electronic data capture (EDC) solution and Clarix™ Interactive Response Technology (IRT) application as the preferred EDC and IRT solutions to Covance clients.
A new clinical research study at Roswell Park Cancer Institute (RPCI) will assess the safety and efficacy of a novel immunotherapy approach to treating advanced melanoma. Developed at RPCI by Roswell Park researchers, the investigational vaccine shows promise for treating tumors in patients with stage III/stage IV melanoma, and perhaps as a future therapy for other solid-tumor cancers as well.
› Verified 2 days ago
| Entity Name | Ocean County Health Department |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235142753 PECOS PAC ID: 9931108180 Enrollment ID: O20170321000126 |
News Archive
An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del mutation in the CFTR gene, which is estimated to represent almost 90 percent of the cystic fibrosis population in the United States.
A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma.
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that it has completed its previously announced acquisition of the Interactive Voice and Web Response Services (IVRS/IWRS) business of Covance Inc. (NYSE: CVD). Phase Forward purchased the Covance business unit for $10 million in cash. As part of the transaction, Phase Forward and Covance have entered into a multi-year marketing agreement to provide Phase Forward's market-leading InForm™ electronic data capture (EDC) solution and Clarix™ Interactive Response Technology (IRT) application as the preferred EDC and IRT solutions to Covance clients.
A new clinical research study at Roswell Park Cancer Institute (RPCI) will assess the safety and efficacy of a novel immunotherapy approach to treating advanced melanoma. Developed at RPCI by Roswell Park researchers, the investigational vaccine shows promise for treating tumors in patients with stage III/stage IV melanoma, and perhaps as a future therapy for other solid-tumor cancers as well.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christine Filippone, NP 1870 Dino Blvd, Toms River, NJ 08755-1343 Ph: (908) 783-5486 | Christine Filippone, NP 1870 Dino Blvd, Toms River, NJ 08755-1343 Ph: (908) 783-5486 |
News Archive
An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del mutation in the CFTR gene, which is estimated to represent almost 90 percent of the cystic fibrosis population in the United States.
A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma.
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that it has completed its previously announced acquisition of the Interactive Voice and Web Response Services (IVRS/IWRS) business of Covance Inc. (NYSE: CVD). Phase Forward purchased the Covance business unit for $10 million in cash. As part of the transaction, Phase Forward and Covance have entered into a multi-year marketing agreement to provide Phase Forward's market-leading InForm™ electronic data capture (EDC) solution and Clarix™ Interactive Response Technology (IRT) application as the preferred EDC and IRT solutions to Covance clients.
A new clinical research study at Roswell Park Cancer Institute (RPCI) will assess the safety and efficacy of a novel immunotherapy approach to treating advanced melanoma. Developed at RPCI by Roswell Park researchers, the investigational vaccine shows promise for treating tumors in patients with stage III/stage IV melanoma, and perhaps as a future therapy for other solid-tumor cancers as well.
› Verified 2 days ago
Eleanor C Dominguez-curatolo, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 111 W Water St, Toms River, NJ 08753 Phone: 732-731-6218 Fax: 732-244-8482 | |
Grant Marshall Myers, PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 509 Main Street, Bldg A, 2nd Floor, Suite B, Toms River, NJ 08753 Phone: 732-301-6904 Fax: 732-605-5771 | |
Jennifer Manzo, APN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 94 Stevens Rd, Children's Specialized Hospital, Toms River, NJ 08755 Phone: 732-797-3801 Fax: 732-797-3812 | |
Mrs. Lalaine Genuino, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 803 Main St, Toms River, NJ 08753 Phone: 732-557-0100 Fax: 732-557-0128 | |
Sarah B Schwartz, APN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 99 Route 37 W, Toms River, NJ 08755 Phone: 732-557-8283 | |
Andrea D Lynn, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 10 Stockton Dr, Toms River, NJ 08755 Phone: 732-363-6655 | |
Kelly St. Marie, MSN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2360 Lakewood Rd, Toms River, NJ 08755 Phone: 732-719-7788 |